Hot Stock Movers On FDA’s Decision (MDT, CHTP, ACUR, AZN, MDCO)
Stocks On FDA’s Decision (MDT, CHTP, ACUR, AZN, MDCO)
(EMAILWIRE.COM, March 17, 2010 ) Dallas, Tx - Medtronic, Inc. (NYSE:MDT) fell 0.60% to $44.87 after hitting an intraday high of $45.24 after today announced it has completed Pre-Market Approval (PMA) submission in consideration for U.S. Food and Drug Administration (FDA) approval for the Medtronic Arctic Front Cardiac CryoAblation Catheter System, which is designed for patients with paroxysmal atrial fibrillation (PAF), an irregular quivering of the upper chambers of the heart that starts and stops on its own. Atrial fibrillation (AF) is the most common heart arrhythmia in the United States, with an estimated three million patients suffering from this condition.
To subscribe these free stock market alerts visit : http://www.SuperHotPennyStocks.com
Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) fell 5.50% to $3.56 after it reported findings from Study 305, a study evaluating the effect of Northera (Droxidopa), an investigational agent being studied for the treatment of neurogenic orthostatic hypotension (NOH), on patients' 24-hour blood pressure (BP) profile.
Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) rose 4% to $5.66 after today it announced that the U.S. Food and Drug Administration ("FDA") has publically announced the scheduling of an April 22, 2010 Advisory Committee meeting to discuss the New Drug Application ("NDA") for Acurox (oxycodone HCl and niacin) Tablets and the results of studies evaluating the addition of niacin for the purpose of reducing the misuse of oxycodone.
AstraZeneca plc (ADR) (NYSE:AZN) and Bristol Myers Squibb Co. (NYSE:BMY) after today announced that the U.S. FDA has accepted for review a New Drug Application for an investigational fixed dose combination of ONGLYZA™ (saxagliptin), a dipeptidyl peptidase-4 inhibitor, and metformin HCl extended-release tablets as a once-daily treatment for type 2 diabetes mellitus in adults. Bristol-Myers Squibb and AstraZeneca submitted the NDA with the U.S. FDA for saxagliptin/metformin HCl extended-release tablets on December 29, 2009.
The Medicines Company (NASDAQ:MDCO) soared 21% to $10.00 after it announced today that it is voluntarily expanding the recall of Cleviprex (clevidipine butyrate) injectable emulsion due to the potential presence of visible particulate matter which has been observed in some vials. Four (4) additional lots of Cleviprex are being recalled.
ABOUT http://www.SuperHotPennyStocks.com
Super Hot Penny Stocks alerts its members through its stock newsletters so that they can invest wisely. Thousands of investors receive our daily stock alerts and have made huge gains in the penny stocks. You can also take advantage of the information provided, to be really successful in the stock market business. We also track various hot stocks of the day, top gainers,52 week high and much more. You can also feature your web link on our website by contacting us through email.
###
Press release service and press release distribution by EmailWire.Com - http://www.emailwire.com/press_release_distribution_lists.php
To subscribe these free stock market alerts visit : http://www.SuperHotPennyStocks.com
Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) fell 5.50% to $3.56 after it reported findings from Study 305, a study evaluating the effect of Northera (Droxidopa), an investigational agent being studied for the treatment of neurogenic orthostatic hypotension (NOH), on patients' 24-hour blood pressure (BP) profile.
Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) rose 4% to $5.66 after today it announced that the U.S. Food and Drug Administration ("FDA") has publically announced the scheduling of an April 22, 2010 Advisory Committee meeting to discuss the New Drug Application ("NDA") for Acurox (oxycodone HCl and niacin) Tablets and the results of studies evaluating the addition of niacin for the purpose of reducing the misuse of oxycodone.
AstraZeneca plc (ADR) (NYSE:AZN) and Bristol Myers Squibb Co. (NYSE:BMY) after today announced that the U.S. FDA has accepted for review a New Drug Application for an investigational fixed dose combination of ONGLYZA™ (saxagliptin), a dipeptidyl peptidase-4 inhibitor, and metformin HCl extended-release tablets as a once-daily treatment for type 2 diabetes mellitus in adults. Bristol-Myers Squibb and AstraZeneca submitted the NDA with the U.S. FDA for saxagliptin/metformin HCl extended-release tablets on December 29, 2009.
The Medicines Company (NASDAQ:MDCO) soared 21% to $10.00 after it announced today that it is voluntarily expanding the recall of Cleviprex (clevidipine butyrate) injectable emulsion due to the potential presence of visible particulate matter which has been observed in some vials. Four (4) additional lots of Cleviprex are being recalled.
ABOUT http://www.SuperHotPennyStocks.com
Super Hot Penny Stocks alerts its members through its stock newsletters so that they can invest wisely. Thousands of investors receive our daily stock alerts and have made huge gains in the penny stocks. You can also take advantage of the information provided, to be really successful in the stock market business. We also track various hot stocks of the day, top gainers,52 week high and much more. You can also feature your web link on our website by contacting us through email.
###
Press release service and press release distribution by EmailWire.Com - http://www.emailwire.com/press_release_distribution_lists.php
Contact Information:
Super Hot Penny Stocks
Robert
Tel: 214 556 6798
Email us
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
Super Hot Penny Stocks
Robert
Tel: 214 556 6798
Email us
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
|
Private Equity, Angel Investing
Equity Alliance / Private Equity, Angel Investing, / IPO, Venture Capital & IR services / Equity Alliance International Equityallianceir.com Penny Stocks to Watch Sign up for hot penny stock picks Gains of 500%+ possible! Premiumstockpicks.com/landing/ Your text Ads & PR Text Ads plus unlimited press releases, One release featured/Day for only $575 per month. Read more on Text Ads & PR Your text Ads Here! Text Ads are only $289 per month. Ads are placed same day. More on Text Ads Advertising |